Amylyx's Big Trial Win, Intapp's AI Push, and HWH's Nasdaq StruggleGlobal Report·Aug 25 at 10:12 AMAMLX+0.41%ORLY+0.58%
Top Executive Quietly Ramps Up Stake in This Under-the-Radar BiotechTip Ranks·Aug 25 at 02:10 AMPTIX+6.00%
Protagenic Therapeutics executive chair Garo H. Armen acquires 20,000 common shares for $13,000PUBT·Aug 24 at 05:20 PMPTIX+6.00%
Protagenic Therapeutics executive chair Garo H. Armen acquires 2,700 common shares for $945PUBT·Aug 20 at 01:24 PMPTIX+6.00%
Protagenic gets FDA pre-IND feedback supporting planned Phase 1 trial for PT00114 in generalized anxiety disorderPUBT·Aug 20 at 12:31 PMPTIX+6.00%
Protagenic Therapeutics FY 2026: Net income $1.37M, EPS $0.59— 10-K SummaryTradingView·Aug 14 at 07:45 PMPTIX+6.00%
Protagenic Therapeutics delays Q2 Form 10-Q filing, misses 5-day extension windowPUBT·Aug 14 at 07:23 PMPTIX+6.00%
Protagenic swings to FY26 net income of $1.37 million; operating expenses rise 74% to $4.5 millionPUBT·Aug 14 at 07:20 PMPTIX+6.00%
Protagenic Therapeutics executive chair Garo H. Armen buys 2,220 shares for $710.4PUBT·Aug 12 at 10:52 PMPTIX+6.00%
Protagenic Therapeutics exec chair Garo H. Armen acquires 685 common shares worth $150.7PUBT·Aug 10 at 02:27 PMPTIX+6.00%
Protagenic Therapeutics exec chair Garo H. Armen acquires 5,000 common shares for $1,294PUBT·Aug 7 at 12:30 AMPTIX+6.00%
